Relmada Therapeutics, Inc. RLMD Allowance for credit losses
Allowance for credit losses at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s allowance for credit losses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s allowance for credit losses?
- Relmada Therapeutics, Inc. (RLMD) reported allowance for credit losses of $1.61M in Q4 2025.
- How has Relmada Therapeutics, Inc.'s allowance for credit losses changed year-over-year?
- Relmada Therapeutics, Inc.'s allowance for credit losses increased by 15.0% year-over-year, from $1.4M to $1.61M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s allowance for credit losses?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s allowance for credit losses has grown at a 20.0% compound annual growth rate (CAGR), from $645K to $1.61M.
- What does allowance for credit losses mean?
- Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.